Hepatocellular carcinoma
Conditions
Interventions
Bevacizumab plus PD-1/PD-L1 inhibitor versus lenvatinib plus PD-1/PD-L1 inhibitor:None
Sponsors
The Fifth Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. HCC diagnosis confirmed histologically or by two concordant radiologic imaging modalities. 2. Fulfillment of the surrogate criteria for portal hypertension: presence of esophageal varices, ascites, or the combination of thrombocytopenia ( 12 cm); meeting any one of these three findings was considered CEPH (clinically evident portal hypertension). 3. Child–Pugh class A or B.
Exclusion criteria
Exclusion criteria: 1. Concomitant malignancy of another origin. 2. Prior history of gastrointestinal bleeding, hepatic encephalopathy, or transjugular intrahepatic portosystemic shunt (TIPS) before treatment. 3. Inadequate follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| portal hypertension; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;progression-free survival; | — |
Countries
CHINA
Contacts
Public ContactLu Yinying
The Fifth Medical Center of the PLA General Hospital
Outcome results
None listed